Recruitment

Recruitment Status
Unknown status

Inclusion Criteria

age over superior to 18
EGFR mutation status known with no activating EGFR mutation
indication of erlotinib therapy after at least one previous therapy
...
age over superior to 18
EGFR mutation status known with no activating EGFR mutation
indication of erlotinib therapy after at least one previous therapy
patients who have signed an informed consent to participate in this study
NSCLC proved by a histological biopsy
life expectancy exceeding 12 weeks
WHO activity score between 0 and 2.

Exclusion Criteria

progressive inflammatory disease
other malignant disease
refusal to sign the consent
...
progressive inflammatory disease
other malignant disease
refusal to sign the consent
life expectancy less than 12 weeks
major adults protected by French law
infection with the HIV virus
contraindication for the initiation of erlotinib

Summary

Conditions
  • No EGFR Activating Mutation
  • Non-small Cell Lung Cancer Metastatic or Non-small Cell Lung Cancer Recurrent
Type
Interventional
Phase
Phase 2
Design
  • Allocation: N/A
  • Intervention Model: Single Group Assignment
  • Masking: None (Open Label)

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Inclusion Criteria

age over superior to 18
EGFR mutation status known with no activating EGFR mutation
indication of erlotinib therapy after at least one previous therapy
...
age over superior to 18
EGFR mutation status known with no activating EGFR mutation
indication of erlotinib therapy after at least one previous therapy
patients who have signed an informed consent to participate in this study
NSCLC proved by a histological biopsy
life expectancy exceeding 12 weeks
WHO activity score between 0 and 2.

Exclusion Criteria

progressive inflammatory disease
other malignant disease
refusal to sign the consent
...
progressive inflammatory disease
other malignant disease
refusal to sign the consent
life expectancy less than 12 weeks
major adults protected by French law
infection with the HIV virus
contraindication for the initiation of erlotinib

Tracking Information

NCT #
NCT02069418
Collaborators
  • University Hospital, Tours
  • Army Hospital, Percy
  • Créteil Hospital
  • University Hospital, Rouen
  • Central Hospital, Nancy, France
  • University Hospital, Toulouse
  • University Hospital, Bordeaux
Investigators
  • Principal Investigator: José HUREAUX, MD, PhD University Hospital, Angers Study Chair: Olivier COUTURIER, MD, PhD University Hospital, Angers
  • José HUREAUX, MD, PhD University Hospital, Angers Study Chair: Olivier COUTURIER, MD, PhD University Hospital, Angers